Table 5 Clinicopathological variables associated with optimal cytoreduction in patients with endometrial carcinoma

Age at recurrence (years)

 < 60

26 (81.3)

1

 ≥ 60

12 (80.0)

1.083

0.231–5.081

ECOG performance status before SCS

 0

32 (78.0)

 1–2

6 (100.0)

NA

NA

FIGO stage at initial diagnosis

 I/II

31 (88.6)

1

1

 III/IV

7 (58.3)

5.536

1.175–26.072

30.777

1.167-811.458

Histology

 Endometrioid

33 (86.8)

1

1

 Non-endometrioid

5 (55.6)

5.280

1.048–26.589

0.820

0.08–8.359

Tumor grade

 G1/G1-G2/G2

18 (94.7)

1

 G2-G3/G3

15 (78.9)

4.8

0.483–47.682

Previous radiotherapy

 No

31 (79.5)

1

 Yes

7 (87.5)

0.554

0.059–5.173

Clinical symptoms at recurrence

 No

21 (80.8)

1

 Symptomatic

17 (81.0)

0.988

0.229–4.264

Size of largest tumor (cm)

 ≤ 6

35 (85.4)

1

 > 6

3 (50.0)

5.833

0.946–35.988

Number of recurrent tumors

 One

23 (95.8)

1

1

 Several

15 (65.2)

12.267

1.389-108.325

20.050

1.222-329.049

DFI before SCS (months)

 < 12

16 (76.2)

1

 ≥ 12

22 (84.6)

0.582

0.135–2.515

Retroperitoneal lymph node metastasis

 No

28 (75.7)

 Yes

10 (100.0)

NA

NA

Distant metastasis

 No

30 (78.9)

1

 Yes

8 (88.9)

0.469

0.051–4.137

Lung metastasis alone

 No

37 (80.4)

 Yes

1 (100.0)

NA

NA

Peritoneal dissemination

 No

33 (89.2)

1

1

 Yes

5 (50.0)

8.250

1.638–41.546

1.833

0.049–69.231

Extended beyond the pelvis

 No

21 (95.5)

1

1

 Yes

17 (68.0)

9.882

1.123–86.985

0.386

0.013–11.546

Ascites

 None

36 (87.8)

1

1

 Yes

2 (33.3)

14.400

2.073-100.012

26.009

0.294-2301.929

Neoadjuvant chemotherapy before SCS

 No

35 (79.5)

 Yes

3 (100.0)

NA

NA